TAIS.F Stock Overview
Through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Taisho Pharmaceutical Holdings Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥59.00 |
52 Week High | JP¥60.00 |
52 Week Low | JP¥38.00 |
Beta | 0.50 |
11 Month Change | 0% |
3 Month Change | -0.39% |
1 Year Change | n/a |
33 Year Change | -12.11% |
5 Year Change | -42.30% |
Change since IPO | 232.39% |
Recent News & Updates
Recent updates
Shareholder Returns
TAIS.F | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 0% | -1.1% | 1.1% |
1Y | n/a | 17.7% | 22.5% |
Return vs Industry: Insufficient data to determine how TAIS.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how TAIS.F performed against the US Market.
Price Volatility
TAIS.F volatility | |
---|---|
TAIS.F Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 9.7% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 14.9% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: TAIS.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine TAIS.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1912 | 8,784 | Akira Uehara | www.taisho-holdings.co.jp |
Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally. It operates through Self-Medication Operation Group and Prescription Pharmaceutical Operation Group segments. The company offers OTC drugs, quasi-drugs, food products, and general medical and hygiene supplies, such as Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatments; the RiUP series of hair re-growth treatment products; the Taisho Kampo series of gastrointestinal treatment products; the Colac series of laxative products; the Naron series and other products for antipyretic analgesics; the Preser series of hemorrhoid treatment products; Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic analgesics; Counterpain topical anti-inflammatory analgesics; Vitacilina, a dermatological treatment product; and VICKS, a cough suppressant throat lozenges and medicated drops.
Taisho Pharmaceutical Holdings Co., Ltd. Fundamentals Summary
TAIS.F fundamental statistics | |
---|---|
Market cap | US$4.64b |
Earnings (TTM) | US$55.64m |
Revenue (TTM) | US$2.12b |
83.4x
P/E Ratio2.2x
P/S RatioIs TAIS.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TAIS.F income statement (TTM) | |
---|---|
Revenue | JP¥320.39b |
Cost of Revenue | JP¥137.22b |
Gross Profit | JP¥183.17b |
Other Expenses | JP¥174.74b |
Earnings | JP¥8.42b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 102.74 |
Gross Margin | 57.17% |
Net Profit Margin | 2.63% |
Debt/Equity Ratio | 0% |
How did TAIS.F perform over the long term?
See historical performance and comparison